Daratumumab, Bortezomib, and Dexamethasone for Previously Treated Multiple Myeloma

J Clin Oncol. 2023 May 10;41(14):2667-2668. doi: 10.1200/JCO.22.02665. Epub 2023 Mar 20.

Authors

Shang-Xiao Huang¹, Peng-Hui Luo¹, Han-Lei Wang¹, Dun-Chang Mo¹, Jian-Feng Huang¹

Affiliation

¹ Shang-Xiao Huang, MD, Peng-Hui Luo, MD, Han-Lei Wang, MD, Dun-Chang Mo, MD, and Jian-Feng Huang, MD, Radiotherapy Department, Nanning Second People's Hospital, Nanning, Guangxi, China.

PMID: 36940404
DOI: 10.1200/JCO.22.02665

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Bortezomib / therapeutic use
Dexamethasone / therapeutic use
Humans
Multiple Myeloma* / drug therapy
Neoplasm Recurrence, Local / drug therapy

Substances

Bortezomib
daratumumab
Dexamethasone